Gryphon Bio
Gryphon Bio is a clinical stage company focused on developing novel blood tests for brain health, leveraging over 20 years of -omic research to identify brain-specific biomarkers in the blood. Their mission is to improve patient lives through innovative diagnostics for various central nervous system (CNS) diseases.
Gryphon Bio
Gryphon Bio is currently seeking investment
Gryphon Bio is seeking a investment in the range of
What We Do
Novel Blood Tests for Brain Health
Gryphon Bio is developing blood tests that serve as biomarkers for brain health, aimed at early disease detection and monitoring.
Diagnostics
Key People
Will Haskins, PhD
CEO & Co-Founder
Kevin Wang, PhD
Co-Founder & Chair of Scientific Advisory Board
Lisa H. Merck, MD MPH MA FACEP
Clinical Advisor
Swetha Mahesula, MS
Research Scientist
Anthony Delizza, MS
Chief Business Officer (CBO)
Devin Jackson, PhD
Senior Research Scientist
News & Updates
Gryphon Bio, in collaboration with CURE and other institutions, received over $1.2M in funding for research on the dynamics of astrocytic activation in post-traumatic epilepsy.